OCT 30, 2014 07:30 AM PDT
Challenges in biomarker testing in non-small cell lung cancer research
Presented at the Cancer: Research, Discovery and Therapeutics Virtual Event
14 44 1511

Speakers:
  • Director, Research Department, Centro di Ricerche Oncologiche di Mercogliano, Naples, Italy
    Biography
      Dr. Normanno earned his Medical Doctor Degree in 1988 at the Medical School of the University of Naples (Italy) Federico II. He received his spacialization in Medical Oncology in 1991, and in Hematology in 2001, at the same university. Between 1990 and 1993, Dr. Normanno completed a postoctoral fellowship studying tumor growth factors at the National Institutes of Health, Bethesda, MD. Since 1993, Dr. Normanno's areas of research have been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the use of antisense oligonucleotides and inhibitors of receptors in experimental models of molecular therapy of carcinomas; and identification of markers of response or resistance to anti EGFR agents. Dr. Normanno is a member of the American Association for Cancer Research, the Italian Tumor Society, and the Italian Cancer Society. He is the author of over 140 papers published in peer reviewed journals. After serving as Senior Investigator, and later, Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Chief of the Cell Biology and Biotherapy Unit at the same Hospital, and since 2006, is also Director of the Research Department.

    Abstract:
    Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved drugs. More than 1500 fusion transcripts have been published to date, but current practices for fusion transcript detection are hampered by high cost and bias. Typically only the top 1-2 commonly observed fusion transcripts are characterized for most samples.

    We have developed a next-generation sequencing solution for highly multiplexed fusion transcript analysis. Using this workflow, hundreds of fusion transcripts can be simultaneously tested in fewer than 24 hours.

    In this presentation, Dr Normanno will present an Ion AmpliSeqTM method for fusion detection and analysis from non-small cell lung cancer research samples.

    Show Resources
    Loading Comments...